 AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock. The post AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth appeared first on Investors Business Daily. 